Phase 3 Clinical Trials With Primary Completion Dates in August 2020

This is a list of Phase 3 trials with primary completion dates in August 2020 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

Symbol Company Primary Completion Date Phase NCT ID Title
ACAD ACADIA Pharmaceuticals Inc. 2020-08-01 Phase 3 NCT03121586 Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
ADMS Adamas Pharmaceuticals, Inc. 2020-08-01 Phase 3 NCT03567057 A Safety and Efficacy Study of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
ARDS Aridis Pharmaceuticals, Inc. 2020-08-01 Phase 3 NCT03816956 Adjunctive Therapy to Antibiotics in the Treatment of S. Aureus Ventilator-Associated Pneumonia With AR-301
CHMA Chiasma, Inc. 2020-08-01 Phase 3 NCT02685709 Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly
DOVA Dova Pharmaceuticals, Inc. 2020-08-01 Phase 3 NCT03471078 Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers
ERYP ERYTECH Pharma S.A. 2020-08-01 Phase 3 NCT03665441 Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC
EXEL Exelixis, Inc. 2020-08-01 Phase 3 NCT03755791 Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy
INTP Integrated Pharmaceuticals, Inc. 2020-08-01 Phase 3 NCT03588429 The Ratio of Hypnotic to Analgesic Potency of Volatile Anesthetics
MDXG MiMedx Group, Inc. 2020-08-01 Phase 3 NCT03414268 Micronized dHACM Injectable for the Treatment of Plantar Fasciitis
OMER Omeros Corporation 2020-08-01 Phase 3 NCT03608033 Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy
SAGE Sage Therapeutics, Inc. 2020-08-01 Phase 3 NCT03665038 A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)
SUPN Supernus Pharmaceuticals, Inc. 2020-08-01 Phase 3 NCT04016779 Evaluation of SPN-812 in Adults With Attention-Deficit/Hyperactivity Disorder
TLRY Tilray, Inc. 2020-08-01 Phase 3 NCT03549819 Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study
VNDA Vanda Pharmaceuticals Inc. 2020-08-01 Phase 3 NCT04327661 Motion Syros: A Randomized Study Investigating the Efficacy of Tradipitant in Treating Motion Sickness
VNDA Vanda Pharmaceuticals Inc. 2020-08-01 Phase 3 NCT04326426 ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection